JP2023546293A5 - - Google Patents
Info
- Publication number
- JP2023546293A5 JP2023546293A5 JP2023548537A JP2023548537A JP2023546293A5 JP 2023546293 A5 JP2023546293 A5 JP 2023546293A5 JP 2023548537 A JP2023548537 A JP 2023548537A JP 2023548537 A JP2023548537 A JP 2023548537A JP 2023546293 A5 JP2023546293 A5 JP 2023546293A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- amino acid
- seq
- acid sequence
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063093255P | 2020-10-18 | 2020-10-18 | |
| US63/093,255 | 2020-10-18 | ||
| PCT/US2021/055311 WO2022082066A1 (en) | 2020-10-18 | 2021-10-15 | Anti-cspg4 binding agents, conjugates thereof and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546293A JP2023546293A (ja) | 2023-11-01 |
| JP2023546293A5 true JP2023546293A5 (enExample) | 2024-10-16 |
Family
ID=78709534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548537A Pending JP2023546293A (ja) | 2020-10-18 | 2021-10-15 | 抗ｃｓｐｇ４結合剤、そのコンジュゲートおよびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250213715A1 (enExample) |
| EP (1) | EP4228704A1 (enExample) |
| JP (1) | JP2023546293A (enExample) |
| CN (1) | CN116782955A (enExample) |
| CA (1) | CA3195865A1 (enExample) |
| WO (1) | WO2022082066A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114836541B (zh) * | 2022-05-23 | 2026-02-17 | 中国药科大学 | 一种利用尿液微囊泡蛋白作为肾癌诊断标志物的应用 |
| WO2024091437A1 (en) * | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5356648B2 (ja) * | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
| DK1912677T3 (da) * | 2005-06-20 | 2014-01-13 | Psma Dev Company L L C | PSMA-antistof-lægemiddel-konjugater |
| WO2013026839A1 (en) * | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| RU2014109038A (ru) * | 2011-08-23 | 2015-09-27 | Рош Гликарт Аг | Антитела к хондроитинсульфат протеогликану меланомы |
| WO2015012904A2 (en) * | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| US20140242083A1 (en) * | 2013-02-26 | 2014-08-28 | Roche Glycart Ag | Anti-mcsp antibodies |
-
2021
- 2021-10-15 CN CN202180078901.0A patent/CN116782955A/zh active Pending
- 2021-10-15 CA CA3195865A patent/CA3195865A1/en active Pending
- 2021-10-15 WO PCT/US2021/055311 patent/WO2022082066A1/en not_active Ceased
- 2021-10-15 US US18/247,628 patent/US20250213715A1/en active Pending
- 2021-10-15 EP EP21811176.3A patent/EP4228704A1/en active Pending
- 2021-10-15 JP JP2023548537A patent/JP2023546293A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012235817B2 (en) | Antibody-drug conjugates | |
| JP2025111463A5 (enExample) | ||
| JP2021516973A5 (enExample) | ||
| JP2021515565A5 (enExample) | ||
| JP2017510559A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2012522513A5 (enExample) | ||
| JP2025183307A5 (enExample) | ||
| JP2015509947A5 (enExample) | ||
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| JP2022533538A5 (enExample) | ||
| JP2015533781A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| JP2022523360A5 (enExample) | ||
| CA3235789A1 (en) | Cancer specific plectin-1 specific antibodies and methods of use thereof | |
| JP2025513721A5 (enExample) | ||
| JP2023546293A5 (enExample) | ||
| JP2020534326A (ja) | イムノコンジュゲートにおけるメチオニン酸化を防止する方法 | |
| JPWO2021251459A5 (enExample) | ||
| JP2024533457A5 (enExample) | ||
| JP2024540536A5 (enExample) | ||
| JP2024502670A5 (enExample) | ||
| JP2022535276A5 (enExample) | ||
| EP4491632A1 (en) | Ror1-targeted binding molecule and use thereof | |
| WO2026035616A1 (en) | Combinations for the treatment of cancer |